Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› UK
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in the UK: Industry-Sponsored Studies

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2881 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Nov 2026, 03:15 UTC
2881
Studies in scope
industry-sponsored, all four open statuses
1386
Recruiting now
open to new participants
545
Lead sponsors
across recruiting studies
Top sites
London 2030 Manchester 676 Birmingham 483 Glasgow 438 Cambridge 426
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Merck Sharp & Dohme LLC115 Hoffmann-La Roche105 Novartis Pharmaceuticals97 Janssen Research & Development, LLC90
Site city
London2030 Manchester676 Birmingham483 Glasgow438 Cambridge426
All 438 cities
Target enrolment
to

Trials in this register

2880 of 2881 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 2
78
Birmingham, Cambridge, Leicester, London, Manchester
2025-11-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Cambridge
2025-11-26
Recruiting
Debiopharm International SA
Phase 3
119
Birmingham, Leeds
2025-11-26
By invitation
Celldex Therapeutics
Phase 3
1,370
Leeds, Bristol, Cambridge, Glasgow, North Finchley
2025-11-25
Recruiting
AstraZeneca
Phase 1
40
Newcastle upon Tyne, Sutton
2025-11-25
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
Cambridge, Cardiff, Edinburgh, Liverpool, London, Nottingham, Oxford
2025-11-25
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Oxford, Aberdeen, Derby, Leicester, Lincoln, London, Southampton, Sutton
2025-11-25
Recruiting
Hoffmann-La Roche
Phase 3
900
Dundee, Exeter, London, Newcastle, Oxford, Plymouth,Devon
2025-11-24
Recruiting
AstraZeneca
Phase 4
56
Harefield, London, Manchester
2025-11-24
Recruiting
TrueLok Elevate PMCF Study
NCT07079774Wound of Skin, Ulcers, Soft Tissue Defect
Orthofix s.r.l.
Observational
153
Hull, Newcastle upon Tyne
2025-11-24
Recruiting
Eli Lilly and Company
Phase 4
3,000
Altrincham, Ashton-under-Lyne, Bolton, Bury, Cheshire, Great Lever, Hyde SK14, Manchester
2025-11-24
Active, closed
Hoffmann-La Roche
Phase 1
3
Cambridge
2025-11-19
Recruiting
XEOS Medical
Observational
850
Coventry
2025-11-19
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Incorporated
Phase 2
26
Birmingham, London, Newcastle upon Tyne, Sheffield
2025-11-19
Recruiting
QED Therapeutics, a BridgeBio company
Phase 2
77
Glasgow, Manchester, Sheffield
2025-11-19
Recruiting
Bayer
Phase 3
111
Bristol, Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds
2025-11-19
Active, closed
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
London, Oxford, Birmingham, Cardiff, Glasgow, Sheffield, Southampton
2025-11-19
Active, closed
Bayer
Phase 2
60
Exeter, London, Sheffield, Sunderland
2025-11-19
Recruiting
BioNTech SE
Phase 1/2
245
Leeds, London, Manchester, Newcastle upon Tyne, Sutton
2025-11-18
Recruiting
Summit Therapeutics
Phase 3
900
Canterbury, London, Northwood, Aberdeen, Edinburgh, Liverpool, Manchester
2025-11-18
Recruiting
iOnctura
Phase 1/2
26
Boston, Belfast, London
2025-11-17
Active, closed
Eli Lilly and Company
Phase 3
250
Birmingham, Blackpool, Bradford on Avon, Bromborough, Cheadle, Hounslow, Oxford, Penzance
2025-11-17
Recruiting
Janssen-Cilag Ltd.
Observational
220
Harrow
2025-11-17
Active, closed
Pfizer
Observational
250
London
2025-11-15
Recruiting
UCB Biopharma SRL
Phase 3
320
London, Salford
2025-11-14
Recruiting
Prima Mente
Observational
1,000
London, Newport, Bradford, Bridgend, Llanelli, Newcastle upon Tyne, Penarth, Reading
2025-11-13
Recruiting
Incyte Corporation
Phase 3
250
London, Sheffield, Walsall
2025-11-13
Recruiting
Incyte Corporation
Phase 2
160
London, Manchester Greater
2025-11-12
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Bath, Birmingham, Edinburgh, Glasgow, London, Manchester, Oxford, Preston
2025-11-12
Recruiting
AstraZeneca
Phase 1/2
83
Bloomsbury, Manchester
2025-11-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
996
Bristol, Yate, London, Corby
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Brighton, Romford, Bristol, Coventry, Glasgow, Leeds, London, Nottingham
2025-11-11
Recruiting
AstraZeneca
Phase 3
420
Glasgow, Scotland, London, Manchester, Newcastle upon Tyne, Nottingham
2025-11-11
Recruiting
AstraZeneca
Phase 1
40
London
2025-11-10
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Liverpool, Dorchester, Wolverhampton, London, Sunderland
2025-11-10
By invitation
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Birmingham, Cambridge, London
2025-11-10
Recruiting
Annexin Pharmaceuticals AB
Phase 2
12
London
2025-11-07
Recruiting
Pfizer
Phase 1
294
Sheffield
2025-11-06
Recruiting
Sanofi
Phase 2
208
London, Leeds
2025-11-06
Recruiting
AstraZeneca
Phase 2
435
Belfast, Birmingham, Brighton, Cambridge, Dundee, Edinburgh, Exeter, Liverpool
2025-11-06
Recruiting
AbbVie
Phase 3
561
Gloucester, London, Bristol, Liverpool, Newcastle upon Tyne, Sunderland
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
300
Liskeard, Newquay, Torquay
2025-11-05
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Glasgow, London, Sulton, Surrey
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
330
Liskeard, Newquay, Torquay, Bushey, London
2025-11-05
Recruiting
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
NCT07189403Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo
Phase 1
40
London
2025-11-04
Recruiting
Takeda
Observational
10
Dorchester, Birmingham, London, Wrexham
2025-11-03
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Brighton, London, Taunton, Guildford, Cardiff
2025-11-03
Recruiting
AstraZeneca
Phase 1
72
London, Manchester
2025-11-03
Recruiting
Medialis Ltd.
Observational
500
Milton Keynes
2025-11-01
Recruiting
AstraZeneca
Phase 3
400
Huddersfield, London, Maidstone, Norwich, Stoke-on-Trent
2025-10-31
Active, closed
A Study With CIT-013 in HS Patients
NCT06993233Hidradenitis Suppurativa (HS)
Citryll BV
Phase 2
108
Cardiff, Chester, London
2025-10-31
Recruiting
Eli Lilly and Company
Phase 3
1,205
London, Plymouth, Stoke-on-Trent, Swansea, West End
2025-10-31
Recruiting
Shionogi
Phase 2
45
Birmingham, London, Newcastle upon Tyne, Salford
2025-10-30
Recruiting
BioNTech SE
Phase 3
558
Brighton, Bristol, Cottingham, Edinburgh, Leeds, London, Oxford, Rhyl
2025-10-30
Recruiting
GlaxoSmithKline
Phase 2
363
North Finchley, Bedford, Bristol Avon, Coventry, Dagenham, Dundee, High Wycombe, Little Baldon
2025-10-30
Recruiting
Bayer
Observational
2,000
Multiple Locations
2025-10-29
Active, closed
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
400
London
2025-10-29
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Gloucester, London, Newcastle, Southampton, Sunderland, York, Belfast
2025-10-28
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Brighton, Newcastle upon Tyne, Liverpool, London
2025-10-28
Recruiting
Beam Therapeutics Inc.
Phase 1
30
London
2025-10-27
Recruiting
Endowave Ltd.
Not applicable
43
London
2025-10-24
Recruiting
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
NCT07218887BAG3 Mutation Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.
Phase 1/2
6
London
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Blackpool, Bristol, Canterbury, Cardiff, Hull, London, Maidstone, Oxford
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Eastbourne, London, Londonderry, Nottingham
2025-10-24
Recruiting
Novo Nordisk A/S
Phase 1
36
London
2025-10-23
Recruiting
Novo Nordisk A/S
Phase 1
30
Birmingham, London, Sheffield
2025-10-23
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Birmingham, London, Metropolitan Borough of Wirral
2025-10-23
Recruiting
Eli Lilly and Company
Phase 3
1,630
Bath, Leeds, London, Manchester, Torquay
2025-10-22
Recruiting
GlaxoSmithKline
Phase 3
1,196
Bedford, Bradford, Corby
2025-10-20
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
DrugEfgartigimod
argenx
Phase 2/3
24
Cardiff, Glasgow, Manchester
2025-10-20
Recruiting
Intervene, Inc.
Not applicable
30
London
2025-10-18
Recruiting
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Stemline Therapeutics, Inc.
Observational
140
London, Oxford
2025-10-17
Recruiting
Pharvaris Netherlands B.V.
Phase 3
48
Bristol, Cambridge, Leicester, London, Newcastle upon Tyne, Plymouth
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Blackpool, Doncaster, Eastbourne, Glasgow, Hayle, Hounslow, London, Newquay
2025-10-16
Active, closed
Gesynta Pharma AB
Phase 2
213
Bradford, Bristol, Corby, Coventry, London, Northwood, Norwich, Orpington
2025-10-15
Not yet open
Assessing Patient Preference for Infusion Systems
NCT07189013Primary Immunodeficiencies (PID), Secondary Immunodeficiencies (SID)
KORU Medical Systems, Inc.
Not applicable
52
London
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
4,500
Aberdeen, Clifton, Enfield, Glasgow, Ipswich, Liverpool, London, Newcastle upon Tyne
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,100
Blackpool, Chester, Eastbourne, Edinburgh, Glasgow, London, Manchester, Southampton
2025-10-15
Recruiting
Vega Therapeutics, Inc
Phase 3
60
London
2025-10-15
Recruiting
Alnylam Pharmaceuticals
Phase 1
50
Glasgow, London, Sheffield, Southampton
2025-10-15
Recruiting
Nurix Therapeutics, Inc.
Phase 2
100
Headington, London, Manchester
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Sutton, London
2025-10-15
Recruiting
Sanofi
Phase 2
54
Cambridge, Oxford
2025-10-14
Recruiting
Conceivable Life Sciences
Not applicable
125
Manchester
2025-10-14
Recruiting
Sanofi
Phase 1/2
104
London
2025-10-09
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Liverpool, London
2025-10-09
Recruiting
Bristol-Myers Squibb
Observational
223
Oxford, Bath, Wolverhampton, London
2025-10-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Truro, London, Birmingham, Leicester
2025-10-08
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Harlow, Leeds, London
2025-10-08
Recruiting
Celgene
Phase 1/2
62
London, Manchester
2025-10-07
Recruiting
Imbria Pharmaceuticals, Inc.
Phase 2
165
London, Glasgow, Oxford
2025-10-06
Recruiting
Pfizer
Phase 2/3
982
Cambridge, London, Edinburgh, Liverpool
2025-10-03
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Birmingham, Cambridge, Glasgow, Greater Manchester, London, Rainhill, Stockport
2025-10-03
Active, closed
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
NCT07033481Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
EIP Pharma Inc
Phase 2
20
Cambridge, Newcastle upon Tyne
2025-10-02
Recruiting
Novo Nordisk A/S
Phase 3
1,280
London, Manchester, Bellshill, Birmingham, Cardiff, Liverpool
2025-10-02
Recruiting
Myota GmbH
Not applicable
156
London
2025-10-02
By invitation
Astria Therapeutics, Inc.
Phase 3
145
Bristol, Cambridge, Frimley, Hampstead, London, Plymouth
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
283
Cambridge, London, Plymouth, Sutton
2025-10-01
Recruiting
ImmunityBio, Inc.
Phase 3
507
Belfast, Truro, Bodelwyddan, Cardiff, London, Southampton, Edinburgh, Guildford
2025-10-01
Recruiting
Sanofi
Phase 3
980
Cottingham, Cambridge, London, Norwich, Rochdale
2025-10-01
Recruiting
AI-Driven Early Detection of Skin Cancer
NCT07144306Skin Cancer Melanoma
Nuvana Healthcare LTD
Observational
100
London
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Cambridge, Edinburgh, Greater Manchester, London, Rainhill, Sheffield, Stockport
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
52
Cambridge, Manchester
2025-09-30
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Derby, Doncaster, Edinburgh, London, Wolverhampton
2025-09-30
Recruiting
WSAUD A/S
Not applicable
70
Nottingham, Sunderland, Wigan
2025-09-30
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Glasgow, London, Sheffield
2025-09-30
Recruiting
Alesta Therapeutics
Phase 1/2
120
Leeds
2025-09-30
Recruiting
Pfizer
Phase 3
680
London, Manchester
2025-09-29
Recruiting
Alfasigma S.p.A.
Phase 3
80
Bristol, Glasgow, Liverpool, London, Sheffield
2025-09-29
Recruiting
iSTAR Medical
Not applicable
60
Colchester, Grimsby, Liverpool, London
2025-09-29
Recruiting
Genentech, Inc.
Phase 2
224
London, Liverpool, Oxford, Cambridge
2025-09-29
Recruiting
AAVantgarde Bio Srl
Phase 1/2
75
London
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Blackburn, Cardiff, Plymouth, Torquay, London, Maidstone, Manchester
2025-09-28
Recruiting
Merck Sharp & Dohme LLC
Phase 2
315
Norwich, Bath, Barnet, Bradford
2025-09-26
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
London
2025-09-26
Recruiting
Sanofi
Phase 3
124
London, Norwich, Oxford
2025-09-26
Recruiting
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Aberdeen, Bristol, High Wycombe, Peterborough, Truro, Edinburgh, Glasgow, Southampton
2025-09-25
Recruiting
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
NCT06776783Respiratory Distress Syndrome, Pre-term Infants
Aerogen Pharma Limited
Phase 3
520
Belfast, London, Preston, Telford
2025-09-24
Recruiting
AstraZeneca
Phase 1/2
164
London, Newcastle upon Tyne
2025-09-24
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
DrugSetmelanotide
Rhythm Pharmaceuticals, Inc.
Phase 3
39
London, Birmingham, Hull
2025-09-23
Recruiting
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
NCT07115953Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
130
Oxford
2025-09-22
Recruiting
Sanofi
Phase 4
218
Dundee, Newcastle upon Tyne, Southampton, Leicester, Bradford, Sheffield
2025-09-22
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
London, Southampton, Salford, Bristol, High Wycombe, Kirkcaldy
2025-09-22
Recruiting
BioNTech SE
Phase 1/2
880
London, Newcastle upon Tyne, Sutton
2025-09-22
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 2
30
Cambridge, Leicester, London, Salford
2025-09-19
Recruiting
PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
NCT06789406Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Overactive Bladder (OAB)
Axonics, Inc.
Not applicable
55
Bradford, Wakefield, Leeds, London
2025-09-18
Recruiting
Sanofi
Phase 3
942
Milton Keynes, London, Southampton, Salford, Chertsey, Reading, Rotherham
2025-09-17
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Bradford, Bristol, Chertsey, London, Newcastle, York
2025-09-17
Recruiting
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 4
50
Cambridge, London, Manchester
2025-09-17
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Canterbury, Nottingham, London, Salford
2025-09-16
Recruiting
Sanofi
Phase 3
942
Bristol, London, Leicester, Harrow, Oxford, Worthing, Bradford
2025-09-16
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
DrugsApitegromab·Nusinersen·Risdiplam
Scholar Rock, Inc.
Phase 2
52
Leeds
2025-09-15
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
414
Antrim, Bath, Birmingham, Leeds, London, Londonderry, Luton, Preston
2025-09-13
By invitation
Lupin Ltd.
Phase 3
176
London
2025-09-12
Recruiting
Annexon, Inc.
Phase 3
30
Edgbaston, Glasgow, Oxford
2025-09-12
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Truro, London, Belfast, Manchester, Nottingham
2025-09-11
Recruiting
LEO Pharma
Phase 2
135
Bristol, London, Newcastle upon Tyne, Salford, Stourbridge
2025-09-11
Recruiting
Pfizer
Phase 3
140
Brighton, London
2025-09-10
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Cottingham, London, Skerray, Southampton, Stevenage
2025-09-10
Recruiting
Bristol-Myers Squibb
Phase 2
182
Birmingham, London, Newcastle upon Tyne
2025-09-09
Recruiting
Intuitive Surgical
Observational
1,200
London, Manchester
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Cambridge, Cottingham, Exeter, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne
2025-09-08
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Ashburton, Belfast, Bellshill, Birmingham, Bristol, Bury St Edmunds, Cambridge, Cardiff
2025-09-06
Recruiting
BeOne Medicines
Phase 3
500
Brighton, Canterbury, Norwich, Oxford, Roundhay, Salisbury
2025-09-04
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Birmingham, London, Manchester, Sutton
2025-09-02
Recruiting
AbbVie
Observational
2,795
London, Oxford, Leeds, Wakefield, Belfast, Cardiff, Walsall, Wolverhampton
2025-09-02
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Belfast, Birmingham, Blackpool, Bodelwyddan, Bradford on Avon, Bristol, Bromborough, Enfield
2025-09-02
Recruiting
Sanofi
Phase 2
30
Milton Keynes, Newcastle upon Tyne
2025-09-02
Recruiting
Ocus Innovation Ireland Limited
Phase 3
234
Belfast, Birmingham, London
2025-09-01
Not yet open
Study to Assess Remote Imaging System to Monitor Diabetic Foot Ulcers
NCT07013448Diabetic Foot Ulcer, Diabetic Foot Ulcer (DFU)
Medical Intelligence Group
Observational
40
Ashton-under-Lyne
2025-09
Recruiting
Entrada Therapeutics, Inc.
Phase 1/2
24
Leeds, Liverpool, London, Manchester, Oxford
2025-08-30
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Guildford, Cambridge, Cardiff, London, Southampton
2025-08-28
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
45
Leicester, Newcastle upon Tyne
2025-08-28
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 3
172
Birmingham, London, Manchester, Cottingham
2025-08-27
Recruiting
BeOne Medicines
Phase 3
351
Cambridge, Dundee, Metropolitan Borough of Wirral
2025-08-27
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Bath, Cardiff, London, Manchester, Nottingham, Swindon, Taunton, Truro
2025-08-26
Recruiting
Pfizer
Phase 3
6,000
Bristol, London, Manchester, Truro, Southampton, Liverpool, Oxford, Shropshire
2025-08-25
Recruiting
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
NCT07151040Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)
One-carbon Therapeutics AB
Phase 1/2
43
Newcastle upon Tyne
2025-08-22
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Salford, Leeds, London
2025-08-22
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
153
Birmingham, Sheffield, Southampton
2025-08-21
Active, closed
Merz Therapeutics GmbH
Phase 3
808
Stoke-on-Trent
2025-08-21
Active, closed
Merz Therapeutics GmbH
Phase 3
997
Stoke-on-Trent
2025-08-21
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
London, Manchester
2025-08-20
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
London
2025-08-19
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
DrugAZD0120
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
London
2025-08-18
Recruiting
e-Sense® Normal Values of Urodynamic Pressures Using e-Sense® Catheters
NCT06905808Lower Urinary Track Symptoms, Urodynamic Exam
Laborie Medical Technologies Inc.
Observational
40
Bristol
2025-08-15
Recruiting
Perspectum
Observational
50
Oxford
2025-08-14
Recruiting
GlaxoSmithKline
Phase 2
220
Birmingham, Bristol, London
2025-08-14
Recruiting
Scarcell Therapeutics S.A.S.
Phase 1
15
Oxford
2025-08-14
Recruiting
Takeda
Phase 3
150
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-08-14
Recruiting
Phase 1 Study of ADX-626 in Healthy Participants
NCT07081503Healthy Adult Participants
ADARx Pharmaceuticals, Inc.
Phase 1
44
London
2025-08-12
Recruiting
BioNTech SE
Phase 1/2
1,438
Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton
2025-08-12
Recruiting
Sanofi
Phase 3
192
London, Manchester
2025-08-12
Recruiting
GlaxoSmithKline
Phase 3
420
London, Portsmouth, Truro
2025-08-11
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
6
Leeds, London
2025-08-11
Recruiting
Merck Sharp & Dohme LLC
Phase 2
250
East Sussex, Truro, London, Edinburgh, Birmingham, Manchester
2025-08-11
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
London, Manchester, Oxford, Bath, Sheffield
2025-08-11
Recruiting
Hvivo
Observational
250
London
2025-08-08
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Edinburgh, Oxford, Aberdeen, London, Newcastle upon Tyne, Salford, Southampton
2025-08-07
Active, closed
AstraZeneca
Phase 3
212
Cambridge, Cardiff, Dundee, London
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Aberdeen, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Greater London, Guildford
2025-08-06
Recruiting
Sanofi
Phase 3
723
Cambridge, Dundee, London, Glasgow, Bath, Guildford, Leeds, Reading
2025-08-06
Recruiting
Pfizer
Phase 3
400
Maidstone, Taunton, Sutton, Coventry, London, Peterborough
2025-08-05
Recruiting
Delcath Systems Inc.
Phase 2
90
Southampton
2025-08-05
Active, closed
Ensoma
Phase 1/2
15
London
2025-08-05
Active, closed
Vir Biotechnology, Inc.
Phase 2
100
London, Manchester, Nottingham
2025-08-05
Recruiting
Autolus Limited
Phase 1
24
Cambridge, Edinburgh, London, Sheffield
2025-08-04
Recruiting
AstraZeneca
Phase 3
800
Bebington, Canterbury, Derby, London, Manchester, Northwood, Truro
2025-08-01
Recruiting
Salutare Group Ltd.
Not applicable
40
London
2025-07-31
Active, closed
Pfizer
Phase 3
208
Brighton, London
2025-07-31
Active, closed
UK ENcorafenib and BInimetinib Real-world Study in Melanoma
NCT07022457Metastatic Melanoma, BRAF V600 Mutation Positive
DrugsEncorafenib·Binimetinib
Pierre Fabre Ltd
Observational
50
Westcliff-on-Sea, Birmingham, Cambridge, Coventry, London, Preston, Southampton
2025-07-31
Recruiting
Amgen
Phase 1
434
London, Sutton
2025-07-31
Recruiting
GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
NCT07127172Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
Neuralink Corp
Not applicable
7
London, Newcastle upon Tyne
2025-07-31
Active, closed
Vir Biotechnology, Inc.
Phase 3
150
London, Manchester, Nottingham
2025-07-30
Recruiting
Study of BHV-1400 in IgA Nephropathy
NCT07054684IgA Nephropathy
Biohaven Therapeutics Ltd.
Phase 1
20
Leicester
2025-07-30
Recruiting
BioMarin Pharmaceutical
Phase 2
60
London
2025-07-30
Recruiting
Eli Lilly and Company
Phase 1/2
68
Bristol, Leeds, Leicester, London
2025-07-30
Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
NCT07144137Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics
Observational
75
Gloucester, London, Southampton, Sunderland, Belfast, Frimley, Manchester
2025-07-30
Active, closed
Boehringer Ingelheim
Phase 1
16
Edinburgh, London
2025-07-29
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2/3
22
London
2025-07-29
Recruiting
AbbVie
Phase 3
120
Cambridge, Sheffield, Liverpool
2025-07-28
Recruiting
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
NCT07148128Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
Auricula Biosciences Inc.
Phase 1/2
110
Headington
2025-07-28
Recruiting
Celgene
Phase 3
400
Cringleford, Canterbury, London, Manchester
2025-07-28
Recruiting
CSL Behring
Phase 3
20
London, Oxford
2025-07-28
Active, closed
Amgen
Phase 3
12,800
Birmingham, Blackpool, Bristol, Cambridge, Chester, Coventry, Dudley, Dundee
2025-07-25
Recruiting
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
London, Southampton
2025-07-25
Recruiting
Celcuity Inc
Phase 3
1,180
Cambridge, Bathgate, Rickmansworth, Maidstone, Taunton, Cottingham, Glasgow, Leeds
2025-07-24
Recruiting
Pharmazz, Inc.
Phase 3
514
Bury, London, Southampton, Wolverhampton, Harrow, Newcastle, Stoke-on-Trent
2025-07-24
Recruiting
Sanofi
Phase 1/2
32
Newcastle upon Tyne
2025-07-23
Recruiting
AbbVie
Phase 1/2
325
Oxford, Manchester
2025-07-23
Recruiting
Pfizer
Phase 3
714
Truro, Sheffield, Southampton, Northwood, London, Taunton, Ipswich, Manchester
2025-07-23
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Birmingham, Blackburn, Bournemouth, Bradford, Bristol, Bromborough, Chichester, Cosham
2025-07-22
Recruiting
4D Molecular Therapeutics
Phase 3
480
Bradford, London, Sunderland
2025-07-22
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Birmingham, Cardiff, Glasgow, Liverpool, London, Oxford, Sheffield, Sutton
2025-07-21
Recruiting
CSL Behring
Observational
200
Cambridge, London, Manchester, Cardiff, Frimley, Birmingham, Leeds
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
London, Leicester, Manchester
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
586
Manchester, London, Edinburgh, Oxford, Birmingham, Leeds, Motherwell, Sheffield
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
Edinburgh, Glasgow, London, Cardiff, Manchester
2025-07-20
By invitation
Cybin IRL Limited
Phase 3
468
Reading
2025-07-18
Recruiting
BioNTech SE
Phase 1/2
482
London, Manchester, Sutton
2025-07-18
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Cambridge, Guildford, Hampstead, London, Maidstone, Manchester, Nottingham
2025-07-17
Active, closed
A Study to Assess THN391 in Subjects With Alzheimer's Disease
NCT06814730Alzheimer Disease, Early Onset
DrugTHN391
Therini Bio, Inc.
Phase 1
19
Edinburgh, London
2025-07-17
Recruiting
AstraZeneca
Phase 2
100
Bristol, Dundee, Headington, London, Norwich
2025-07-17
Active, closed
Philip Morris Products S.A.
Not applicable
16
Belfast
2025-07-17
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
Aberdeen, Edinburgh, Southampton, London, Oxford, Bath, Birmingham
2025-07-16
Recruiting
Bristol-Myers Squibb
Phase 3
426
Preston, Chertsey, Cambridge, London, Motherwell, Redruth, Sheffield, Stafford
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Birmingham, London, Oxford, Coventry, Cardiff, Manchester
2025-07-16
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Cambridge, Edinburgh, Leicester, Newcastle upon Tyne
2025-07-16
Recruiting
Takeda
Phase 3
347
London, Birmingham, Canterbury, Hull, Leicester, Nottingham, Preston, Sheffield
2025-07-15
Active, closed
Aligos Therapeutics
Phase 2
200
Glasgow, Leicester, London
2025-07-15
Recruiting
Apreo Health, Inc.
Not applicable
250
London
2025-07-15
Recruiting
Hoffmann-La Roche
Observational
700
Birmingham, Guildford, Leeds, Middlesbrough, Norfolk
2025-07-15
Recruiting
Creo Medical Limited
Observational
18
London
2025-07-14
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
London, Metropolitan Borough of Wirral, Crownhill, Plymouth, Liverpool
2025-07-14
Recruiting
Galderma R&D
Observational
1,000
London, Southampton, Watford, Kings Lynn, Harrogate, Sheffield, Birmingham, Leeds
2025-07-14
Recruiting
CSL Behring
Phase 2
70
Liverpool, London
2025-07-10
Active, closed
ViiV Healthcare
Phase 1
107
London
2025-07-10
Active, closed
Glycomine, Inc.
Phase 2/3
50
Birmingham
2025-07-09
Recruiting
ELEVATE-HFpEF Clinical Study
NCT06678841Heart Failure With Preserved Ejection Fraction (HFpEF)
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
700
Leeds, London, Manchester
2025-07-09
Recruiting
Adelphi Real World
Observational
700
Bath
2025-07-07
Active, closed
Sanofi
Phase 2
105
Northwich, Bury, Cambridge, London
2025-07-07
Recruiting
Janssen Research & Development, LLC
Phase 1
140
Manchester, Sutton
2025-07-07
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
360
Cambridge, London
2025-07-03
Recruiting
Radiation Free Study
NCT06549348Aortic Aneurysm
Philips Clinical & Medical Affairs Global
Not applicable
182
London
2025-07-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Bellshill, Birmingham, Cardiff, London, Manchester
2025-07-02
Active, closed
Upstream Bio Inc.
Phase 2
666
Milton Keynes, Edgbaston, High Wycombe, Chesterfield, Newton Abbot, Romford, Glasgow, Preston
2025-07-02
Not yet open
Santersus AG
Not applicable
73
Birmingham, Edinburgh, Liverpool, London
2025-07-01
Not yet open
eXRt Intelligent Healthcare
Not applicable
30
Belfast
2025-07-01
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Oxford, Sutton, Windsor, London
2025-07-01
Not yet open
GyroGlove Use in Essential Tremor Patients
NCT05958030Essential Tremor
GyroGear Ltd
Not applicable
30
Cambridge, Newcastle, Oxford
2025-07
Recruiting
Azafaros B.V.
Phase 3
147
London, Manchester
2025-06-30
Active, closed
Mundipharma Research Limited
Phase 2
60
Cambridge, Derby, Dundee, Edinburgh, Leeds, London, Manchester
2025-06-30
Recruiting
AbbVie
Phase 1/2
602
London, Birmingham, Cardiff
2025-06-30
Recruiting
Azafaros B.V.
Phase 3
72
London, Manchester
2025-06-30
Recruiting
Entrada Therapeutics, Inc.
Phase 1/2
24
Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2025-06-30
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
London, Dundee, Huddersfield, Colchester, Orpington, Nottingham, Blackpool, Leicester
2025-06-30
Active, closed
Immunovant Sciences GmbH
Phase 2
180
Cambridge, Liverpool, London, Swindon, Truro
2025-06-30
Recruiting
Ipsen
Phase 2
132
Exeter, Fazakerley, London, Luton
2025-06-30
Recruiting
Novo Nordisk A/S
Phase 2
200
Birmingham, High Wycombe, London, Middlesbrough, Southampton
2025-06-30
Recruiting
Hoffmann-La Roche
Phase 3
75
London, Manchester
2025-06-27
Recruiting
Novo Nordisk A/S
Phase 2
200
Birmingham, High Wycombe, London, Middlesbrough, Southampton
2025-06-27
Recruiting
AstraZeneca
Phase 2
987
Bradford, Cottingham, Glasgow, Harrow, London, Newcastle upon Tyne, Thetford, Wythenshawe
2025-06-27
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Leeds, Salford
2025-06-27
Recruiting
Bristol-Myers Squibb
Phase 1
236
Nottingham
2025-06-27
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
London
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
350
Bristol, Dundee, Exeter, London
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Airdrie, Ashington, Belfast, Bournemouth, Bridgend, Bristol, Chichester, Dundee
2025-06-25
Recruiting
MowOot and Trans-anal Irrigation fOr coNstipation
NCT06833684Constipation Chronic Idiopathic
usMIMA S.L.
Not applicable
40
London
2025-06-25
Active, closed
DBV Technologies
Phase 3
480
Glasgow, Leicester, London, Manchester, Sheffield, Southampton
2025-06-24
Recruiting
Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)
NCT06885931Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI), Chronic Pelvic Pain, Urge Urinary Incontinence
Amber Therapeutics Ltd
Not applicable
86
Bristol, London
2025-06-24
Recruiting
GlaxoSmithKline
Phase 3
961
Manchester, Portsmouth, Uxbridge, Bedford, Corby, Dagenham, Edinburgh, Glasgow
2025-06-23
Recruiting
Enterra Medical, Inc.
Not applicable
148
London, Manchester
2025-06-23
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Sheffield, Leeds, London, Swansea
2025-06-23
Active, closed
Calluna Pharma AS
Phase 2
150
Birmingham, Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Southampton
2025-06-20
Recruiting
Bladder EpiCheck European Haematuria Study
NCT06818136Hematuria, Cystoscopy, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
Nucleix Ltd.
Observational
800
Dunfermline, Cambridge, Edinburgh, London, Surrey Quays
2025-06-20
By invitation
BioMarin Pharmaceutical
Phase 3
140
London
2025-06-20
Recruiting
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta
W.L.Gore & Associates
Observational
1,500
Bristol
2025-06-19
Recruiting
Pfizer
Phase 2
620
Dundee, London, Norwich, Chichester, Belfast, High Wycombe, Sheffield
2025-06-19
Recruiting
EXACT Therapeutics AS
Phase 2
25
Cambridge, Hammersmith, Sutton
2025-06-19
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Cornwell, London, Merthyr Tydfil, Salford, Surrey
2025-06-19
Recruiting
Step Pharma, SAS
Phase 2
50
Sheffield, Cardiff, London, Oxford, Southampton
2025-06-18
Active, closed
Incyte Corporation
Phase 3
159
Glasgow, London, Metropolitan Borough of Wirral, Nottingham, Sheffield, Walsall
2025-06-17
Active, closed
AbbVie
Phase 3
573
London, North Finchley, Glasgow, Manchester, Oxford, Birmingham, Stockport
2025-06-17
Recruiting
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
NCT06839235Primary Hyperoxaluria Type 1 (PH1)
Arbor Biotechnologies
Phase 1/2
23
Birmingham, London
2025-06-16
Recruiting
Relay Therapeutics, Inc.
Phase 2
277
London
2025-06-13
Recruiting
GlaxoSmithKline
Phase 1/2
346
Manchester
2025-06-11
Recruiting
BeOne Medicines
Phase 3
630
Bournemouth, Headington, Leeds, London, Metropolitan Borough of Wirral, Newcastle upon Tyne, Truro
2025-06-11
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
London, Newcastle upon Tyne, Sheffield
2025-06-10
Recruiting
BioNTech SE
Phase 3
480
Brighton, Bristol, Cambridge, Cottingham, Coventry, Edinburgh, Exeter, London
2025-06-10
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
156
London, Oxford
2025-06-10
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Dudley, London
2025-06-09
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Belfast, Birmingham, Blackpool, Bradford, Bristol, Cambridge, Cardiff, Dundee, Scotland
2025-06-09
Active, closed
Biogen
Phase 3
255
London, Oxford, Sheffield
2025-06-09
Recruiting
Nova Laboratories Limited
Observational
180
Basildon, Cardiff, London, Manchester, Oxford
2025-06-09
Recruiting
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
NCT06797999Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
Adcendo ApS
Phase 1/2
270
London
2025-06-05
Recruiting
GlaxoSmithKline
Phase 2
80
Boston, London, Manchester
2025-06-05
Recruiting
Boehringer Ingelheim
Phase 2
300
Camberley, Gloucester, Harrow, Liverpool, London, Newcastle upon Tyne, Sunderland, Westcliff-on-Sea
2025-06-05
Active, closed
Stoke Therapeutics, Inc
Phase 3
170
Glasgow, London, Sheffield
2025-06-04
Recruiting
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
NCT06891443Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders
DrugSepofarsen
Laboratoires Thea
Phase 3
32
London
2025-06-04
Active, closed
Incyte Corporation
Phase 3
9
Cardiff, Glasgow, Leeds, Leicester, London
2025-06-04
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Brighton, Cambridge, Canterbury, Colchester, Edinburgh, Liverpool, London, Plymouth
2025-06-04
Recruiting
AstraZeneca
Phase 3
15,100
Birmingham, Bournemouth, Bridgend, Bristol, Calow, Cambridge, Cardiff, Chippenham
2025-06-04
Recruiting
Sanofi
Phase 2
99
Bury, Cambridge, Dagenham, London
2025-06-03
Recruiting
Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study
NCT05881798Deep Vein Thrombosis, Venous Thromboembolism, Pulmonary Embolism
Cook Research Incorporated
Observational
82
Leeds, Hull, Liverpool
2025-06-02
Recruiting
BONESUPPORT AB
Observational
128
Oxford
2025-06-02
Recruiting
W.L.Gore & Associates
Observational
158
Glasgow
2025-05-30
Recruiting
Neurocrine Biosciences
Phase 3
200
London, Salford, Sheffield, Southampton
2025-05-30
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Glasgow, London
2025-05-30
Recruiting
AbbVie
Phase 2
110
Cambridge, Exeter, London
2025-05-28
Recruiting
Swedish Orphan Biovitrum
Phase 2
156
Leeds, London, Oxford
2025-05-28
Active, closed
AstraZeneca
Phase 3
3,103
Chesterfield, Chippenham, Corby, Coventry, Harrow, Hull, London, Northwood
2025-05-28
Recruiting
Idoven 1903 S.L.
Observational
2,200
Glasgow
2025-05-27
Recruiting
Immunovant Sciences GmbH
Phase 3
231
Birmingham, Glasgow, London
2025-05-27
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
Birmingham, Newcastle upon Tyne, Cardiff, Sutton
2025-05-26
Recruiting
EURO-STIM Registry
NCT06971796Obstructive Sleep Apnea, Obstructive Sleep Apnea (OSA)
Inspire Medical Systems, Inc.
Observational
1,000
London, Manchester
2025-05-26
Recruiting
Chiesi Farmaceutici S.p.A.
Observational
10
London
2025-05-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester
2025-05-22
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Cottingham, Bristol, Cardiff, Coventry, Dundee, Glasgow, London, Manchester
2025-05-22
Recruiting
Eikon Therapeutics
Phase 2/3
740
Belfast, London, Southampton
2025-05-22
Active, closed
Upstream Bio Inc.
Phase 2
396
Cottingham, Glasgow, Chertsey, Perth, Bradford, Oxford
2025-05-21
Active, closed
Swedish Orphan Biovitrum
Phase 4
252
Birmingham, Cardiff, London, Manchester
2025-05-21
Recruiting
Pfizer
Phase 2
252
Cambridge, Manchester, London, Bradford, Crumpsall, Wakefield
2025-05-20
Active, closed
Boehringer Ingelheim
Phase 1/2
5
London
2025-05-20
Recruiting
GMP Powdered Substitutes in PKU and TYR
NCT06941532Phenylketonuria, Tyrosinemia
Nutricia UK Ltd
Not applicable
40
Birmingham
2025-05-20
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Bristol, Clydebank, Exeter, Halifax, Harrow, London
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Leeds, Oxford, Plymouth
2025-05-20
Recruiting
Eli Lilly and Company
Phase 4
279
Leeds, Oxford, Plymouth
2025-05-20
Recruiting
SecuraBio
Phase 3
124
Sutton, Glasgow, Leicester, London, Manchester, Nottingham, Oxford
2025-05-19
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Leeds, London, Woodville South
2025-05-19
Recruiting
Astellas Gene Therapies
Observational
50
Leeds, London, Oxford
2025-05-19
Recruiting
Akrivia Health
Observational
50,000
Oxford
2025-05-16
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Dudley, Liverpool, London
2025-05-16
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
London, Stoke-on-Trent
2025-05-15
Recruiting
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
NCT06861361Symptomatic Severe Aortic Stenosis
Ceric Sàrl
Not applicable
1,180
Belfast, Brighton, Cambridge, Cottingham, Coventry, London, Newcastle upon Tyne, Sheffield
2025-05-15
Recruiting
Crainio Non-invasive ICP Monitor for TBI
NCT06453733Traumatic Brain Injury
Crainio Ltda
Not applicable
54
London
2025-05-15
Active, closed
Boehringer Ingelheim
Phase 1
91
London, Sutton
2025-05-14
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
Salford, Dudley, London
2025-05-14
Recruiting
Eli Lilly and Company
Phase 1
104
Holbeck, Leeds
2025-05-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Cambridge, London, Exeter, Birmingham, Northwood, Sutton, Devon
2025-05-13
Recruiting
Hoffmann-La Roche
Phase 3
425
Bristol, Bury, Llanrhystud, London, Newcastle upon Tyne, Stockport
2025-05-12
Active, closed
Merck Sharp & Dohme LLC
Phase 2
130
Cambridge, London, Glasgow
2025-05-12
Recruiting
Aktiia SA
Observational
15,000
London
2025-05-12
Active, closed
Sanofi
Phase 2
71
Gloucester, Manchester, Newcastle upon Tyne
2025-05-12
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
London
2025-05-12
Recruiting
Biogen
Phase 3
454
London, Preston, Leicester, Sheffield, Stoke-on-Trent
2025-05-08
Recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
NCT06662162Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
i-Lumen Scientific AUS PTY LTD
Not applicable
100
Belfast, London, Middlesex, Sunderland
2025-05-07
Active, closed
Byondis B.V.
Phase 1
7
Manchester, Sutton
2025-05-07
Recruiting
Takeda
Phase 3
225
Aberdeen, Rhyl, Leicester, Lincoln, High Heaton, Sunderland, Birmingham, Cambridge
2025-05-06
Active, closed
Cartesian Therapeutics
Phase 3
128
Birmingham, Sheffield
2025-05-06
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
London, Liverpool, Sutton, Manchester
2025-05-06
Recruiting
AstraZeneca
Phase 3
1,220
Cambridge, Leeds, London, Manchester
2025-05-06
Active, closed
FARAPULSE Workflow Assessment Registry
NCT06656884Atrial Fibrillation (AF)
Boston Scientific Corporation
Observational
524
Bournemouth, Cambridge, Leicester, Newcastle upon Tyne, Southampton
2025-05-06
Active, closed
Mediar Therapeutics
Phase 2
168
Birmingham, Cambridge, Edinburgh, Oxford
2025-05-05
Active, closed
Hoffmann-La Roche
Phase 2
285
Blackpool, Leicester, Shipley, Coventry, Northwood, Orpington
2025-05-05
Recruiting
BioNTech SE
Phase 1/2
594
Bristol, Leeds, Liverpool, London, Manchester, Preston
2025-05-02
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
59
London
2025-05-01
Recruiting
Elemental 028 Extra Case Studies
NCT06877923Gastrointestinal Disease, Inflammatory Bowel Disease (IBD), Short Bowel, Malabsorption
Nutricia UK Ltd
Not applicable
30
Trowbridge
2025-05-01
Recruiting
AstraZeneca
Phase 1
72
Glasgow, London, Southampton
2025-05-01
By invitation
Novo Nordisk A/S
Observational
1,250
West Bromwich, Barnsley, Hull, London, Luton, Tooting
2025-05-01
Not yet open
Non-invasive Detection of Coronary Artery Stenosis
NCT06750016Coronary Arterial Disease (CAD)
Nilocas
Observational
20
London
2025-05
Recruiting
Hoffmann-La Roche
Phase 1
405
Birmingham, London
2025-04-30
Active, closed
Pediatric Expansion Study of the Sentio System
NCT06976086Hearing Loss, Conductive, Hearing Loss, Mixed, Single Sided Deafness
Oticon Medical
Not applicable
50
Birmingham, London
2025-04-30
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Chichester, London, Manchester, Tyne and Wear
2025-04-30
Recruiting
Epax Norway AS
Not applicable
90
Cardiff
2025-04-30
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Glasgow, London
2025-04-29
Active, closed
Pharming Technologies B.V.
Phase 2
12
Leeds
2025-04-29
Active, closed
Hoffmann-La Roche
Observational
44
London, Manchester
2025-04-29
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
118
London, Harrow
2025-04-28
By invitation
Vertex Pharmaceuticals Incorporated
Phase 2
44
Glasgow, London, Sheffield
2025-04-28
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
London, Birmingham, Guildford
2025-04-24
Recruiting
AbbVie
Phase 2
390
London, Oxford, Sutton, Birmingham, Manchester
2025-04-24
Recruiting
Arrowhead Pharmaceuticals
Phase 3
288
Torquay, London, Dundee
2025-04-24
Recruiting
BioNTech SE
Phase 1/2
380
Cambridge, Cardiff, Leeds, London, Manchester, Sutton
2025-04-23
By invitation
QED Therapeutics, a BridgeBio company
Phase 2/3
24
Manchester, Sheffield, Glasgow
2025-04-22
Active, closed
Novartis Pharmaceuticals
Phase 1/2
15
Sheffield, London
2025-04-22
Recruiting
EMBRACE Tremor BiFUS
NCT06974916Essential Tremor
InSightec
Not applicable
100
Liverpool
2025-04-22
Recruiting
Vanda Pharmaceuticals
Phase 3
420
Great Yarmouth, Leicester, Liverpool, London, Sheffield
2025-04-21
Recruiting
AstraZeneca
Phase 1/2
150
Bristol
2025-04-21
Active, closed
AstraZeneca
Observational
2,000
London
2025-04-17
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Exeter, Cottingham, London, Oxford, Stoke-on-Trent, Birmingham, Leeds, Cambridge
2025-04-17
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
London
2025-04-16
Recruiting
ModernaTX, Inc.
Phase 2
180
Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield
2025-04-16
Recruiting
Neurocrine Biosciences
Phase 3
850
Southampton, Sheffield, London, Manchester
2025-04-16
By invitation
Egoo Health Aps
Observational
20
Birmingham
2025-04-15
Active, closed
Janssen Research & Development, LLC
Phase 3
752
Dudley, Harrow, Kings Lynn, London, Reading, Salford, Southampton, Wakefield
2025-04-15
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
605
Brighton, Fulham, Sutton, London, Manchester
2025-04-15
Recruiting
Société des Produits Nestlé (SPN)
Not applicable
25
Nottingham
2025-04-14
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Bristol, Aylesbury, Exeter, Plymouth, Middlesbrough, Lincoln, London, Oxford
2025-04-11
Recruiting
AstraZeneca
Phase 3
830
Blackpool, Glasgow, Guildford, Hull, Northwood, Oxford
2025-04-10
Recruiting
BeOne Medicines
Phase 3
250
Aberdeen, Birmingham, Bournemouth, London, Southampton
2025-04-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool
2025-04-09
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
Plymouth, Torquay, London
2025-04-09
Recruiting
Hoffmann-La Roche
Phase 3
450
Blackpool, Colchester, Essex, Edinburgh, Harlow, London, Northwood, Oxford, Sheffield
2025-04-09
Recruiting
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
NCT06846554Pulmonary Arterial Hypertension
Apollo Therapeutics Ltd
Phase 2
48
London, Bath, Cambridge, Clydebank, Sheffield
2025-04-09
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
168
Coventry, London, Manchester
2025-04-09
Active, closed
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06459869Locally Advanced Rectal Cancer (LARC)
Akamis Bio
Phase 1
33
London, Sutton
2025-04-07
Recruiting
Gilead Sciences
Phase 3
695
Manchester
2025-04-04
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
Basildon, Bristol, Leeds, Leicester, London
2025-04-04
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
London
2025-04-03
Active, closed
QIAGEN Gaithersburg, Inc
Observational
1,500
Manchester
2025-04-03
Recruiting
AZD5305 hADME in Patients With Advanced Solid Malignancies
NCT06713369Locally Advanced or Metastatic Solid Tumor
DrugSaruparib
AstraZeneca
Phase 1
8
Liverpool, Manchester
2025-04-02
Active, closed
Philip Morris Products S.A.
Not applicable
290
Enfield, Glasgow, High Wycombe, London, Manchester, Metropolitan Borough of Wirral, Preston, Rochdale
2025-04-02
Recruiting
Pfizer
Phase 3
674
East Sussex, Dundee, London, Worthing
2025-04-01
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Oxford
2025-04-01
Not yet open
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Major Depressive Disorder (MDD)
NCT06470035Major Depressive Disorder \(MDD, Depressive Disorder, Major
Neurovalens Ltd.
Not applicable
170
Belfast
2025-04
Recruiting
OrthoPureXT Multiligament PMCF Study
NCT05655156Multiligament Knee Injuries
Tissue Regenix Ltd
Not applicable
28
Stoke-on-Trent
2025-04
Recruiting
Nimbus Wadjet, Inc.
Phase 1/2
134
London, Manchester
2025-03-31
Recruiting
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06980116Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1
85
Leeds, Plymouth
2025-03-31
Recruiting
AbbVie
Observational
700
Milton Keynes, Truro, Cheltenham, Portsmouth, Airdrie, Nottingham, Manchester, Newcastle upon Tyne
2025-03-28
Recruiting
Eli Lilly and Company
Phase 2
200
Birmingham, Blackpool, Bristol, Bromborough, Newcastle, Newquay, Nuneaton, Poole
2025-03-28
Recruiting
AstraZeneca
Phase 3
600
Bath, Cambridge, Leeds, London, Manchester, Northwood, Taunton
2025-03-27
Active, closed
Apogee Therapeutics, Inc.
Phase 1
31
Bradford, Manchester
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
510
Belfast, Dundee, London, Manchester, Plymouth, Sutton
2025-03-27
Recruiting
Eli Lilly and Company
Phase 3
700
Birmingham, East Sussex, Huddersfield, London, Manchester, Torquay
2025-03-27
Recruiting
Accession Therapeutics Limited
Phase 1/2
72
Glasgow, Cardiff, Leeds, Oxford
2025-03-21
Recruiting
Bayer
Phase 1/2
450
Manchester, Sutton
2025-03-21
Active, closed
Immutep S.A.S.
Phase 3
756
Birmingham, Guildford, Manchester
2025-03-21
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Leeds, Bristol, Cardiff, London, Southampton
2025-03-20
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Plymouth, Hampstead, Bristol, Cambridge, Frimley, London
2025-03-20
Recruiting
Daiichi Sankyo
Phase 3
582
Cambridge, London, Manchester, Oxford, Sheffield
2025-03-19
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Bristol, Glasgow, Salford, Southampton
2025-03-18
Recruiting
AstraZeneca
Phase 3
990
Bradford, Brighton, Cottingham, Glasgow, Halifax, Leeds, Portsmouth, Tyne and Wear
2025-03-18
Active, closed
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Cambridge, Nottingham
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Cambridge, Harrow, Liverpool, London, Newcastle upon Tyne, North Shields, Nottingham
2025-03-17
Active, closed
Amgen
Phase 3
1,105
Belfast, Birmingham, Blackpool, Bristol, Ely, Glasgow, Hull, Leicester
2025-03-17
Recruiting
Synergy Spine Solutions
Observational
50
Birmingham, London
2025-03-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Truro, London, Nottingham, Taunton, Birmingham, Cardiff, Leeds
2025-03-16
Active, closed
Hoffmann-La Roche
Phase 4
274
Cardiff, Leeds, Liverpool, London, Newcastle upon Tyne, Wolverhampton
2025-03-14
Recruiting
AstraZeneca
Phase 3
11,300
Aberdeen, Chesterfield, Dundee, Gatley, Glasgow, London, Norwich, Penzance
2025-03-14
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Cambridge, Glasgow, London, Manchester
2025-03-13
Active, closed
Celgene
Phase 3
960
Glasgow, Northwood, London, Manchester
2025-03-13
Active, closed
AstraZeneca
Phase 2
82
Cambridge, London, Manchester, Metropolitan Borough of Wirral
2025-03-12
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Cambridge, London, Oxford, Manchester, Newcastle upon Tyne, Sheffield
2025-03-12
Active, closed
Vir Biotechnology, Inc.
Phase 3
124
London, Manchester, Nottingham
2025-03-12
Active, closed
Amgen
Phase 3
3,853
Belfast, Birmingham, Blackpool, Bristol, Cornwall, Ely, Glasgow, Hull
2025-03-12
Recruiting
Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases
NCT06891365Healthy Volunteers, Hepatic Steatosis
Novo Nordisk A/S
Phase 1
48
Harrow
2025-03-12
Recruiting
UCB Biopharma SRL
Phase 3
40
Bristol, Manchester, Nottingham, Stoke-on-Trent
2025-03-11
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
DrugIntismeran autogene
Merck Sharp & Dohme LLC
Phase 2
308
Glasgow, London, Torquay
2025-03-11
Recruiting
Pfizer
Phase 3
723
Bristol, Milton Keynes, Hull, London, Fazakerley, York, Glasgow, Sheffield
2025-03-11
Active, closed
Takeda
Phase 3
601
London, Coventry, Bradford, Harlow, Stoke-on-Trent, Wolverhampton
2025-03-10
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Birmingham, London
2025-03-07
Recruiting
Inari VISION Registry
NCT06600542Pulmonary Embolism
Inari Medical
Observational
1,000
Bristol, Glasgow, London, Manchester, Newcastle, Romford, Swindon
2025-03-07
Recruiting
AbbVie
Phase 1/2
252
Leicester, Cardiff
2025-03-06
Active, closed
Eli Lilly and Company
Phase 3
643
Birmingham, Blackburn, Blackpool, Bradford on Avon, Bromborough, Cheadle, Hounslow, Oxford
2025-03-05
Recruiting
BeOne Medicines
Phase 3
300
Birmingham, Bournemouth, Glasgow, Headington, London, Metropolitan Borough of Wirral, Plymouth
2025-03-05
Active, closed
AstraZeneca
Phase 2
63
Birmingham, Leicester, Liverpool, London, Manchester
2025-03-05
Recruiting
GlaxoSmithKline
Phase 1/2
305
Glasgow, London
2025-03-04
Recruiting
Tyra Biosciences, Inc
Phase 2
92
London, Sheffield
2025-03-04
Recruiting
AstraZeneca
Phase 3
5,000
Bradford, Bristol, Canterbury, Cardiff, Dundee, Glasgow, Hounslow, London
2025-03-03
Active, closed
BicycleTx Limited
Phase 2
66
London
2025-03-03
Recruiting
BioNTech SE
Phase 2
60
Cardiff, Leeds, London, Manchester
2025-03-03
Recruiting
AstraZeneca
Phase 3
840
Cambridge, Coventry, Dundee, London, Manchester, Sutton
2025-03-01
Not yet open
Multivitamin Intervention and Cognitive Function
NCT06795789Healthy Adult, Cognitive Measures
Braincare Limited
Not applicable
30
London
2025-03-01
Recruiting
Xim Limited
Observational
256
London
2025-03-01
Recruiting
Novartis Pharmaceuticals
Phase 3
9
Southampton
2025-02-28
Recruiting
Bayer
Phase 1
148
London, Glasgow, Sutton
2025-02-28
Recruiting
Incyte Corporation
Phase 3
600
Birmingham, Dudley, Ipswich, Liverpool, London, Poole, Redhill, Salford
2025-02-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
London, Liverpool, Manchester
2025-02-27
Active, closed
iOnctura
Phase 2
85
Northwood, Bebington, Glasgow, London, Southampton
2025-02-27
Recruiting
Takeda
Phase 3
171
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-02-27
Recruiting
Tensi+ European Post-Market Clinical Follow-Up
NCT07205445Overactive Bladder
Stimuli Technology
Observational
500
Bristol, Cambridge, London
2025-02-27
Recruiting
Daiichi Sankyo
Phase 3
726
Birmingham, Cardiff, Dundee, Hull, Leeds, London, Londonderry, Manchester
2025-02-27
Recruiting
Sitryx Therapeutics Ltd
Phase 1
149
Manchester, Merthyr Tydfil
2025-02-26
Active, closed
Amgen
Phase 2
252
Manchester
2025-02-26
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
181
London, Glasgow
2025-02-26
Recruiting
Bristol-Myers Squibb
Phase 3
530
Central Middlesbrough, Aberdeen, Manchester, Metropolitan Borough of Wirral
2025-02-25
Recruiting
Amgen
Phase 3
844
Portsmouth, Leeds, London
2025-02-25
Recruiting
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
NCT06712823Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2
200
Birmingham, London
2025-02-25
Recruiting
Prevail Global Study
NCT06535854Coronary Artery Disease
Medtronic Vascular
Not applicable
1,205
Newcastle upon Tyne
2025-02-24
Active, closed
BioMarin Pharmaceutical
Phase 1
6
Edinburgh, London, Southampton
2025-02-21
Recruiting
SharpTx
Not applicable
170
Exeter, Preston, Oxford, Taunton, London
2025-02-20
Active, closed
Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis
NCT06507865Aneurysm, Dissection, Aortic, TAA Thoracoabdominal Aortic Aneurysm, Thoracic Aortic Aneurysm
W.L.Gore & Associates
Observational
155
London
2025-02-20
Active, closed
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
56
Leeds, London, Manchester
2025-02-19
Active, closed
Gilead Sciences
Phase 2
39
London
2025-02-18
Recruiting
GlaxoSmithKline
Phase 2
120
Glasgow, Leeds West Yorkshire, London, Sutton
2025-02-18
Recruiting
Novo Nordisk A/S
Phase 3
510
Cambridge, London
2025-02-17
Recruiting
Lupin Ltd.
Phase 3
176
London
2025-02-13
Recruiting
AbbVie
Phase 3
420
London, Gillingham, Aberdeen, Leeds, Stockport
2025-02-13
By invitation
Longboard Pharmaceuticals
Phase 3
324
Cardiff, Newcastle upon Tyne, Glasgow, London
2025-02-12
Active, closed
Sanofi
Phase 3
231
London, Oxford, Bradford, Newcastle upon Tyne
2025-02-12
Recruiting
Xim Limited
Not applicable
500
London
2025-02-10
Active, closed
Novo Nordisk A/S
Phase 3
400
Bristol, Cambridge, Coventry, Liverpool, London, Swansea, Taunton
2025-02-10
Recruiting
Dianthus Therapeutics
Phase 3
256
Manchester, Oxford
2025-02-10
Active, closed
AbbVie
Phase 3
468
Poole, Brighton, London, Thetford, Oxford
2025-02-10
Recruiting
Janssen Research & Development, LLC
Phase 3
50
Birmingham, Liverpool, London, Oxford
2025-02-10
Active, closed
GlaxoSmithKline
Phase 2
307
Bradford, London, Newcastle upon Tyne
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
London
2025-02-07
Active, closed
Zura Bio Inc
Phase 2
80
Aberdeen, Bath, Dundee, Leeds, Liverpool, London, Stoke-on-Trent
2025-02-06
Recruiting
Janssen Research & Development, LLC
Phase 1/2
190
Sutton
2025-02-06
Active, closed
Sanofi
Phase 3
216
Wigan, London, Taunton
2025-02-06
Recruiting
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Phase 1/2
108
Basingstoke, Tooting, Whitechapel, Birmingham, Cardiff, Leeds, Liverpool, London
2025-02-06
Recruiting
Maze Therapeutics
Phase 2
74
Leicester, London
2025-02-05
Recruiting
Richmond Research Institute
Observational
1,000
London
2025-02-05
By invitation
Atos Medical AB
Not applicable
22
London
2025-02-05
Recruiting
Bristol-Myers Squibb
Phase 1/2
416
London, Glasgow, Birmingham, Newcastle upon Tyne
2025-02-04
Recruiting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
DrugAcalabrutinib
AstraZeneca
Phase 4
60
Bournemouth, Oxford, Plymouth, Romford, Stockton, Sutton Coldfield
2025-02-04
Active, closed
Viridian Therapeutics, Inc.
Phase 3
320
Bristol, Cambridge, London, Newcastle
2025-02-03
Recruiting
NovoCure GmbH
Phase 3
741
London, Northwood, Birmingham, Cambridge, Cardiff, Edinburgh, Liverpool, Manchester
2025-02-03
Active, closed
WATER IV Prostate Cancer
NCT06651632Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
280
Basingstoke, Colney, London
2025-02-03
Recruiting
Physio-Assist
Not applicable
468
Belfast, Cambridge, Edinburgh, London, Newcastle upon Tyne
2025-02-03
Rows per page Showing 501–1000 of 2880
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site. Derived from ClinicalTrials.gov. Retrieved 6 November 2026. https://priyalifescience.com/clinical-trials-uk?page=2

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,881 studies in total at the last sync on 06 Nov 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in the UK?

1,386 of the 2,880 studies in this register are recruiting new participants as of the 06 Nov 2026, 03:15 UTC sync. A further 65 have not yet opened recruitment, 1,342 are active but closed to new participants, and 87 are enrolling by invitation only. Eligibility for any study is decided by its study team.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Breast Cancer (47) Multiple Myeloma (47) Obesity (40) Chronic Lymphocytic Leukemia (29) Ovarian Cancer (29) Heart Failure (27) Carcinoma, Non-Small-Cell Lung (26) Ulcerative Colitis (25) Non-Small Cell Lung Cancer (24) Non-small Cell Lung Cancer (23) Crohn's Disease (22) Neoplasms (21) Asthma (20) Prostate Cancer (20) Solid Tumors (20)
→

Browse trials by city

London (2030) Manchester (676) Birmingham (483) Glasgow (438) Cambridge (426) Oxford (373) Leeds (323) Bristol (277) Liverpool (259) Newcastle upon Tyne (258) Edinburgh (256) Cardiff (245) Sutton (231) Sheffield (216) Leicester (212)
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.